On 11 November 2015, orphan designation (EU/3/15/1569) was granted by the European Commission to Dr Jens Steinbrink, Germany, for pentetrazol for the treatment of idiopathic hypersomnia.
The sponsorship was transferred to Balance Therapeutics, Limited, United Kingdom, in January 2016.
The sponsorship was transferred to Pharma Gateway AB, Sweden in October 2019.
|Disease / condition||
Treatment of idiopathic hypersomnia
|Date of first decision||
|EU designation number||
Review of designation
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.